Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Pharmacokinetic variability of oxcarbazepine in epileptic patients.
Autore:
Viola, MS; Bercellini, MA; Saidon, P; Rubio, MC;
Indirizzi:
Univ Buenos Aires, Fac Farm & Bioquim, Catedra Farmacol, RA-1113 Buenos Aires, DF, Argentina Univ Buenos Aires Buenos Aires DF Argentina RA-1113 Aires, DF, Argentina Hosp Ramos Mejia, Div Neurol, Buenos Aires, DF, Argentina Hosp Ramos Mejia Buenos Aires DF Argentina , Buenos Aires, DF, Argentina Hosp Ramos Mejia, Cent Lab, Buenos Aires, DF, Argentina Hosp Ramos Mejia Buenos Aires DF Argentina , Buenos Aires, DF, Argentina
Titolo Testata:
MEDICINA-BUENOS AIRES
fascicolo: 6, volume: 60, anno: 2000,
pagine: 914 - 918
SICI:
0025-7680(2000)60:6<914:PVOOIE>2.0.ZU;2-E
Fonte:
ISI
Lingua:
SPA
Soggetto:
POPULATION PHARMACOKINETICS; ANTIEPILEPTIC DRUGS;
Keywords:
oxcarbazepine; OCBZ; MHD; population pharmacokinetics;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
15
Recensione:
Indirizzi per estratti:
Indirizzo: Viola, MS Univ Buenos Aires, Fac Farm & Bioquim, Catedra Farmacol, Junin 956, RA-1113 Buenos Aires, DF, Argentina Univ Buenos Aires Junin 956 Buenos Aires DF Argentina RA-1113 na
Citazione:
M.S. Viola et al., "Pharmacokinetic variability of oxcarbazepine in epileptic patients.", MEDICINA, 60(6), 2000, pp. 914-918

Abstract

The aim of this study was to analyze the population pharmacokinetics of oxcarbazepine (OCBZ) measuring the serum level of its active metabolite, monohydroxylated oxcarbazepine (MHD). We studied a group of patients with symptomatic and cryptogenic epilepsy treated with OCBZ monotherapy orally, at least for 3 weeks. The mean doses, age and weight of the patients were 17.9 +/- 7.8 mg/kg/day, 35.6 +/- 16.4 years and 70.3 +/- 19.2 kg, respectively. Blood samples were taken before the first morning dose of OCBZ and MHD levels were determined by HPLC. A linear relationship was found between OCBZ dose and MHD serum level (r = 0.844, p < 0.001). The MHD serum concentration (mg/l) can be predicted as 0.85 x OCBZ dose (mg/kg). There was a significantcorrelation between observed and predicted MHD concentrations for each patient. The mean MHD clearance (CI/F) calculated was 4.05 +/- 1.69 l/h, with a coefficient variation of 41%. It was independent of dose, age and weight and followed a non normal distribution. The half-life of MHD was 10.50 +/- 3.17 hours. The influence of other antiepileptic drugs on MHD pharmacokinetics was analyzed by comparing the CI/F medians from groups of patients receiving concomitant drugs with OCBZ monotherapy group where no significant differences were found. The results can be used to estimate a priori OCBZ doses, in order to individualize the treatment.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 24/09/20 alle ore 05:02:55